Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036784 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
A Phase 1 study, sponsored by MBX Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT06036784 is a Phase 1 study that has completed, run by MBX Biosciences. The registered enrollment target is 69 participants.
The verdict
NCT06036784, a Phase 1 study, has completed, sponsored by MBX Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts. Part A involves a single dose of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part B involves repeat doses of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part C involves the evaluation of rosuvastatin and acetaminophen pharmacokinetics in the presence and absence of MBX 1416.
Interventions
- DRUG Placebo
- DRUG MBX 1416 (Part A)
- DRUG MBX 1416 (Part B)
- DRUG MBX 1416 (Part C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06036784
The ClinicalTrials.gov registry entry for NCT06036784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06036784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06036784 about?
NCT06036784 is a clinical study titled "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects". The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts. Part A involves a single dose of MBX 1416 or placebo taken as a subcutaneous...
What is the current status of trial NCT06036784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2023-09-18. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT06036784?
The interventions under investigation include: Placebo (DRUG), MBX 1416 (Part A) (DRUG), MBX 1416 (Part B) (DRUG), MBX 1416 (Part C) (DRUG).
Who is sponsoring clinical trial NCT06036784?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.